The Sandhoff Disease Therapeutics Market size is anticipated to attain a value of US$ 10 million in 2023 and US$ 17.91 million by 2033, exhibiting a CAGR of 6% during the period from 2023 to 2033. Between 2018 and 2022, the Sandhoff Disease Treatments market grew at a CAGR of 4%.
Current research indicates that Sandhoff disease is a rare condition that affects 1 in 1,000,000 individuals. The increasing demand for these treatments is expected to drive the development of new and innovative therapies, thus propelling the industry forward in the years to come.
A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16729
One potential treatment for Sandhoff disease is gene therapy, which involves delivering a functional copy of the missing enzyme into the patient’s cells to restore their ability to break down GM2 ganglioside. This therapy has the potential to halt or delay disease progression, thereby enhancing the patient’s quality of life.
Key Takeaways from the Market Study
- From 2018 to 2022, the Sandhoff Disease Therapeutics market grew at a CAGR of 4%.
- The global Sandhoff Disease Therapeutics market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Sandhoff Disease Therapeutics Market is expected to reach US$ 17.91 Million.
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the Sandhoff Disease Therapeutics market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Sandhoff Disease Therapeutics.” says an FMI analyst
Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16729
Market Competition
Key players in the market include pharmaceutical companies such as Bioasis Technologies Inc, Nuo Therapeutics Inc, Sio Gene Therapies, Inc., INTRABIO IRELAND LIMITED, Sanofi, ROIVANT SCIENCES LTD, Azafaros, Polaryx Therapeutics, Abbott Medtronic, and Merck & Co., Inc. along with healthcare providers and technology companies among other global players.
- In November 2020, Axovant Gene Therapies Ltd., a company developing gene therapies, announced that the FDA has cleared its Investigational New Drug Application to start a registrational study of AXO-AAV-GM2 gene therapy for Tay-Sachs and Sandhoff diseases. AXO-AAV-GM2 is the first gene therapy to receive IND clearance for these diseases. The FDA letter confirms that all issues related to the clinical hold have been resolved. This marks a significant moment for the GM2 gangliosidosis community and is the second IND clearance for Axovant’s gene therapy pipeline in the last year, with the first being AXO-AAV-GM1 for GM1 gangliosidosis.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Sandhoff Disease Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Request Customization of Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-16729
Key Segments Profiled in the Sandhoff Disease Therapeutics Industry Survey
Therapy:
- Gene Therapy
- Enzyme Replacement Therapy
- Stem Cell Therapy
Type:
- Acute infantile Sandhoff disease
- Subacute juvenile Sandhoff disease
- Late-onset Sandhoff disease
End-Users:
- Hospitals
- Homecare
- Specialty Clinics
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
